tiprankstipranks
Advertisement
Advertisement

BIOA Stock Latest News

BioAge Labs price target lowered to $20 from $23 at Morgan Stanley
The FlyBioAge Labs price target lowered to $20 from $23 at Morgan Stanley
11d ago
BIOA
BioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
PremiumRatings
BioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
12d ago
BIOA
BioAge Labs price target lowered to $21 from $52 at Citi
PremiumThe Fly
BioAge Labs price target lowered to $21 from $52 at Citi
12d ago
BIOA
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
PremiumRatings
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
13d ago
BIOA
BioAge Labs reports Q2 EPS (58c), consensus (62c)
PremiumThe Fly
BioAge Labs reports Q2 EPS (58c), consensus (62c)
13d ago
BIOA
Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
PremiumRatingsShrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
15d ago
BIOA
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
Premium
The Fly
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
18d ago
NVO
BIOA
BioAge Labs price target lowered to $25 from $36 at Roth Capital
Premium
The Fly
BioAge Labs price target lowered to $25 from $36 at Roth Capital
18d ago
NVO
BIOA
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
PremiumRatings
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
18d ago
BIOA
Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential
PremiumRatings
Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential
18d ago
BIOA
BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi
PremiumThe Fly
BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi
18d ago
NVO
BIOA
BioAge Labs price target lowered at Jefferies after Novo trial miss
PremiumThe Fly
BioAge Labs price target lowered at Jefferies after Novo trial miss
18d ago
NVO
BIOA
BioAge Labs price target lowered to $50 from $60 at Oppenheimer
PremiumThe FlyBioAge Labs price target lowered to $50 from $60 at Oppenheimer
18d ago
BIOA
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
Premium
Ratings
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
1M ago
BIOA
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
Premium
Company Announcements
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
2M ago
BIOA
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
PremiumThe Fly
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
2M ago
BIOA
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
PremiumCompany Announcements
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
2M ago
8K
BIOA
BioAge Labs initiated with a Buy at Roth Capital
PremiumThe Fly
BioAge Labs initiated with a Buy at Roth Capital
3M ago
BIOA
AMD, Under Armour downgraded: Wall Street’s top analyst calls
PremiumThe Fly
AMD, Under Armour downgraded: Wall Street’s top analyst calls
3M ago
UA
AMD
BioAge Labs initiated with a Buy at BTIG
PremiumThe FlyBioAge Labs initiated with a Buy at BTIG
3M ago
BIOA
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
Premium
Ratings
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
3M ago
BIOA
BioAge Labs reports Q1 EPS (52c), consensus (63c)
Premium
The Fly
BioAge Labs reports Q1 EPS (52c), consensus (63c)
3M ago
BIOA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >